STAT

The fireman of global health: The WHO’s emergencies chief is put to the test

The WHO's emergencies chief, Mike Ryan, spent a quarter-century responding to outbreaks and other crises. He was also once used as a human shield in Iraq.

GENEVA — Walk into Mike Ryan’s office here on the orderly campus of the World Health Organization and you are in a train station.

Staff members rush in to see the agency’s ruddy, fast-talking emergencies chief to seek guidance on the various disease outbreaks they are trying to end. People crowd into the office where a pair of assistants are stationed, waiting their turn. When Ryan’s door is closed, it’s not long before a hand is rapping on the other side.

Ryan and his staff are firemen, the paramedics of global health. Their work is all front-burner stuff. Half an hour spent on this is 30 minutes not spent on that. There is the Ebola crisis — and a massive measles outbreak — in the Democratic Republic of the Congo, the Rohingya refugee situation in Bangladesh, too many crises to count in Yemen and Syria.

“It exhausts me at times,” said Ryan, who at 55 remains affable and quick to laugh despite the circumstances. Still, Ryan said, he is unwilling to change the tempo or restrict the access, knowing that the higher up one gets in an organization, the more reluctant colleagues are to be the conveyors of unwelcome information. “I don’t want them to hide the bad news,” he insisted.

The WHO employs all kinds of experts. Its scientists set standards for the appropriate use of antibiotics or vaccines, among

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks